Clovis gains after FDA approves Rubraca

FDA granted accelerated approval to Rubraca rucaparib (CO-338) from Clovis Oncology Inc. (NASDAQ:CLVS) to treat women with advanced ovarian cancer who have received two or more chemotherapies and whose tumors have germline or somatic BRCA mutations as identified by a companion diagnostic.

The approval came well ahead of Rubraca's Feb. 23 PDUFA date. The NDA was under Priority Review...